Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 90/100

Termination Rate

25.0%

1 terminated out of 4 trials

Success Rate

0.0%

-86.5% vs benchmark

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed with results

Key Signals

1 with results0

Data Visualizations

Phase Distribution

4Total
P 1 (1)
P 2 (2)
P 3 (1)

Trial Status

Recruiting2
Not Yet Recruiting1
Terminated1

Clinical Trials (4)

Showing 4 of 4 trials
NCT07342478Phase 3RecruitingPrimary

ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL

NCT07459608Phase 2Not Yet Recruiting

Efficacy and Safety of Lisaftoclax (APG-2575) Monotherapy in Patients With Indolent Lymphoma

NCT06708897Phase 1RecruitingPrimary

A Phase 1 Study of ZE50-0134 in Relapsed and Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Select Low-grad Lymphomas

NCT00714259Phase 2Terminated

Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade B Cell Malignancies

Showing all 4 trials

Research Network

Activity Timeline